Households where someone tests positive for COVID-19 now have an oral drug option to protect the people around them. The FDA approved Xocova, known generically as ensitrelvir, as the first oral antiviral cleared specifically to prevent symptomatic COVID-19 after a known exposure. The approval covers adults and adolescents aged 12 and older and is based on a phase 3 trial that showed a 67% relative risk reduction in symptomatic infection through day 10. Developed by Japanese pharmaceutical company Shionogi, the drug is taken as a five-day pill course: three tablets on day one, then one tablet on each of the next four days.
Why a post-exposure pill changes the calculus for households
Until now, people exposed to COVID-19 at home had two broad defenses: vaccination and behavioral measures like masking and ventilation. Neither is designed to be started after an exposure event and finished within a week. Xocova fills that gap. The drug targets the SARS-CoV-2 3CL protease, blocking viral replication early enough to prevent symptoms from developing in exposed contacts. That mechanism already proved effective in treatment trials; the new approval extends it to prevention.
The practical effect could reach beyond what the 67% efficacy figure alone suggests. When a household member tests positive, the availability of a simple pill course may change how quickly contacts seek testing and how strictly they isolate. If people act faster because a concrete medical option exists, secondary attack rates could fall by more than the drug’s direct pharmacological effect. That behavioral amplification is difficult to model but plausible: oral contraceptives, antiretroviral PEP for HIV, and oseltamivir for influenza all shifted health-seeking behavior once they became accessible. Whether the same pattern holds here will depend on prescriber awareness, insurance coverage, and how quickly pharmacies stock the drug.
For high-risk households, the calculus may be even more pronounced. Multigenerational homes, caregivers of immunocompromised people, and workers who cannot easily isolate could see Xocova as a way to reduce the chance that one positive test cascades into multiple illnesses. In those settings, a five-day course that meaningfully lowers the odds of symptomatic infection may function as a bridge between vaccination campaigns and non-pharmaceutical precautions, rather than a replacement for either.
SCORPIO-PEP trial results and the regulatory path
The approval rests on the SCORPIO-PEP trial, a randomized, double-blind, placebo-controlled phase 3 study of household contacts of people with confirmed COVID-19. Registered as NCT05897541 and sponsored by Shionogi, the trial enrolled participants who began the five-day regimen of 375 mg on day one followed by 125 mg on days two through five. Participants who received ensitrelvir experienced a 67% relative risk reduction in symptomatic COVID-19 through day 10 compared with placebo.
The New England Journal of Medicine manuscript describing the prevention trial reports that the primary endpoint was the development of symptomatic, PCR-confirmed COVID-19 within 10 days of randomization, and that the benefit of ensitrelvir emerged early in the follow-up window. According to the published analysis, the absolute risk of symptomatic infection was lower in the treatment arm, though the magnitude of that absolute reduction varied by baseline risk.
Shionogi first presented the SCORPIO-PEP data as a late-breaking presentation at the Conference on Retroviruses and Opportunistic Infections (CROI) in early 2025. The FDA accepted the new drug application later that year under a Fast Track designation, signaling that regulators viewed the prevention indication as addressing an unmet medical need. The agency’s formal approval announcement on May 31, 2026, confirmed that Xocova is authorized for post-exposure prophylaxis in people 12 and older who have had close contact with someone with COVID-19.
Ensitrelvir is not new to regulators outside the United States. Japan granted the drug its first standard approval on March 5, 2024, initially for treatment of COVID-19. Shionogi had also completed two earlier phase 3 treatment trials, SCORPIO-HR and SCORPIO-SR, which tested the same five-day oral course in nonhospitalized adults with mild to moderate disease during the Omicron era. Those studies established the drug’s safety profile and dosing framework, giving the FDA a broader evidence base to evaluate alongside the prevention-specific SCORPIO-PEP data. Together, the treatment and prevention trials allowed regulators to examine consistent dosing, pharmacokinetics, and adverse-event patterns across different patient populations.
How Xocova fits alongside existing COVID-19 tools
With vaccines and treatment antivirals already in use, Xocova enters a landscape where multiple layers of protection are possible but not always fully deployed. Vaccination remains the primary strategy to prevent severe disease, yet uptake has plateaued in many communities. Oral treatments like nirmatrelvir-ritonavir are reserved for people who are already symptomatic and at higher risk of progression. Xocova’s post-exposure indication occupies the window between exposure and illness, aiming to keep people from getting sick in the first place.
That positioning could matter for public health planning. During surges, widespread use of post-exposure prophylaxis in high-risk settings-such as long-term care facilities, shelters, and crowded households-might blunt the number of symptomatic cases needing evaluation and potential treatment. However, the real-world impact will depend on how quickly clinicians recognize eligible exposures and how accessible the drug proves to be in routine care.
Cost and coverage will be central to that question. If insurers treat Xocova like other outpatient antivirals, prior authorization requirements or high copays could limit uptake, especially among lower-income households that often face higher exposure risks. Conversely, if public programs or targeted subsidies support access for high-risk groups, the preventive potential of the drug could be more fully realized.
Gaps in the evidence and what to watch next
Several questions remain open. The published SCORPIO-PEP results report a top-line efficacy number, but full participant-level adverse-event tables and subgroup analyses from the New England Journal of Medicine manuscript have not yet been released in granular detail. Without those breakdowns, clinicians cannot yet tell whether the drug works equally well across age groups, vaccination statuses, or variant exposures, or whether certain subgroups experience more side effects.
Independent FDA review documents and the final approved prescribing information have not been publicly posted through the Drugs@FDA portal as of the approval date. Those documents typically contain the agency’s own statistical analysis, its assessment of manufacturing quality, and any post-marketing requirements Shionogi must fulfill. Until they appear, the public record relies heavily on company-issued summaries and the peer-reviewed trial publication, leaving some uncertainty about how regulators weighed specific safety signals or rare adverse events.
Resistance is another open file. Protease inhibitors can drive viral escape mutations over time, a pattern well documented with HIV and hepatitis C drugs. Long-term follow-up data on whether repeated community use of ensitrelvir selects for resistant SARS-CoV-2 strains remain limited to company summaries rather than independent registry updates. Surveillance programs tracking antiviral resistance will need to incorporate ensitrelvir now that it has a prevention indication, particularly in regions where the drug is widely used for both treatment and prophylaxis.
There are also practical implementation questions. Clinicians will need clear guidance on which exposures justify a prescription, how to time the first dose relative to the index case’s symptom onset, and how to coordinate Xocova with ongoing vaccination efforts. Public health agencies may eventually issue prioritization frameworks, for example recommending the drug primarily for contacts who are older, immunocompromised, or living in congregate settings, but those policies have not yet been fully articulated.
For now, Xocova’s approval marks a notable expansion of the COVID-19 toolkit: a short oral course that can be started after a known exposure, with trial data suggesting a substantial reduction in the risk of developing symptomatic infection. As more regulatory documents and real-world studies emerge, clinicians and policymakers will be better positioned to define where this new option fits-whether as a niche safeguard for the highest-risk households or a more broadly used layer of protection alongside vaccines, masks, and early treatment.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
